Natera Shares Slide on Wider-than-Expected Loss, CEO Transition

Dow Jones11-06

Shares of Natera slumped after the company posted a wider-than-expected loss in its latest quarter and said its chief executive is stepping down.

The stock declined 20% to $292.47 in after-hours trading on Thursday. Shares closed the market session down 7% at $363.76.

The molecular diagnostics and genetics testing company logged a third-quarter loss of $59.9 million, or 42 cents a share, compared with $87.5 million, or 64 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 28 cents a share.

The wider-than-expected loss came as Natera posted revenue growth of 34% to $794 million. Analysts expected $707.5 million.

Total operating expenses were up 20% to $576.1 million, driven by headcount growth to support new product offerings and increases in clinical trial expenses.

The company raised its top-line guidance as a result to $3.01 billion to $3.04 billion, compared with its previous forecast of $2.85 billion to $2.91 billion.

Natera on also said that Chief Executive Steve Chapman will step down from the position, and remain a consultant and an adviser to the board.

Solomon Moshkevich was appointed CEO, effective immediately. Moshkevich, who joined the company in 2011, was most recently president of the clinical diagnostics segment, where he led the company's oncology expansion.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681886848?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-06 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681886848","market":"hk","top_or_hot":-1,"title":"Natera Shares Slide on Wider-than-Expected Loss, CEO Transition","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Shares of Natera slumped after the company posted a wider-than-expected loss in its latest quarter and said its chief executive is stepping down. \n</p>\n<p>\n  The stock declined 20% to $292.47 in after-hours trading on Thursday. Shares closed the market session down 7% at $363.76. \n</p>\n<p>\n  The molecular diagnostics and genetics testing company logged a third-quarter loss of $59.9 million, or 42 cents a share, compared with $87.5 million, or 64 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 28 cents a share. \n</p>\n<p>\n  The wider-than-expected loss came as Natera posted revenue growth of 34% to $794 million. Analysts expected $707.5 million. \n</p>\n<p>\n  Total operating expenses were up 20% to $576.1 million, driven by headcount growth to support new product offerings and increases in clinical trial expenses. \n</p>\n<p>\n  The company raised its top-line guidance as a result to $3.01 billion to $3.04 billion, compared with its previous forecast of $2.85 billion to $2.91 billion. \n</p>\n<p>\n  Natera on also said that Chief Executive Steve Chapman will step down from the position, and remain a consultant and an adviser to the board. \n</p>\n<p>\n  Solomon Moshkevich was appointed CEO, effective immediately. Moshkevich, who joined the company in 2011, was most recently president of the clinical diagnostics segment, where he led the company's oncology expansion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera Shares Slide on Wider-than-Expected Loss, CEO Transition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera Shares Slide on Wider-than-Expected Loss, CEO Transition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-11-06 06:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Shares of Natera slumped after the company posted a wider-than-expected loss in its latest quarter and said its chief executive is stepping down. \n</p>\n<p>\n  The stock declined 20% to $292.47 in after-hours trading on Thursday. Shares closed the market session down 7% at $363.76. \n</p>\n<p>\n  The molecular diagnostics and genetics testing company logged a third-quarter loss of $59.9 million, or 42 cents a share, compared with $87.5 million, or 64 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 28 cents a share. \n</p>\n<p>\n  The wider-than-expected loss came as Natera posted revenue growth of 34% to $794 million. Analysts expected $707.5 million. \n</p>\n<p>\n  Total operating expenses were up 20% to $576.1 million, driven by headcount growth to support new product offerings and increases in clinical trial expenses. \n</p>\n<p>\n  The company raised its top-line guidance as a result to $3.01 billion to $3.04 billion, compared with its previous forecast of $2.85 billion to $2.91 billion. \n</p>\n<p>\n  Natera on also said that Chief Executive Steve Chapman will step down from the position, and remain a consultant and an adviser to the board. \n</p>\n<p>\n  Solomon Moshkevich was appointed CEO, effective immediately. Moshkevich, who joined the company in 2011, was most recently president of the clinical diagnostics segment, where he led the company's oncology expansion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2681886848","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2681886848","pubTimestamp":1793919060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Natera slumped after the company posted a wider-than-expected loss in its latest quarter and said its chief executive is stepping down.The stock declined 20% to $292.47 in after-hours tradin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc.","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","GNOM":"Global X Genomics & Biotechnology ETF","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","HELX":"Franklin Genomic Advancements ETF","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC"},"translate_title":"Natera 股价因亏损超出预期、首席执行官换届而下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1.5,"HELX":0.6,"GNOM":0.6},"content_text":"Shares of Natera slumped after the company posted a wider-than-expected loss in its latest quarter and said its chief executive is stepping down. \n\n\n  The stock declined 20% to $292.47 in after-hours trading on Thursday. Shares closed the market session down 7% at $363.76. \n\n\n  The molecular diagnostics and genetics testing company logged a third-quarter loss of $59.9 million, or 42 cents a share, compared with $87.5 million, or 64 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 28 cents a share. \n\n\n  The wider-than-expected loss came as Natera posted revenue growth of 34% to $794 million. Analysts expected $707.5 million. \n\n\n  Total operating expenses were up 20% to $576.1 million, driven by headcount growth to support new product offerings and increases in clinical trial expenses. \n\n\n  The company raised its top-line guidance as a result to $3.01 billion to $3.04 billion, compared with its previous forecast of $2.85 billion to $2.91 billion. \n\n\n  Natera on also said that Chief Executive Steve Chapman will step down from the position, and remain a consultant and an adviser to the board. \n\n\n  Solomon Moshkevich was appointed CEO, effective immediately. Moshkevich, who joined the company in 2011, was most recently president of the clinical diagnostics segment, where he led the company's oncology expansion.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681886848","isCrawlerRequest":true}